A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
Exposure to common environmental chemicals, especially in combination, is linked to an increased risk of multiple sclerosis.
The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback